Glemaz - synthetic hypoglycemic drug used in type 2 diabetes.
Pharmacological action Glemaza
Active substance Glemaza stimulates secretion and release of insulin sensitivity and improves muscle and adipose tissue peripheral to the action of its own insulin. Use of the drug reduces the severity of the ever-present oxidative stress in the body in type 2 diabetes.
Furthermore, according to the instructions provided Glemaz antiplatelet, anti-atherogenic and anti-oxidant effect and helps to reduce insulin resistance in a greater degree than similar drugs in this group.
Glemaz produced in the form of flat rectangular light green tablets containing 4 mg of glimepiride. On 5 and 10 pieces in blister.
According to the instructions Glemaz used in type 2 diabetes as a monotherapy and in combination therapy with insulin or metformin.
The drug, like counterparts Glemaza contraindicated taken when:
- Type 1 diabetes;
- State, accompanied by malabsorption of food and the development of hypoglycemia, including infectious diseases;
- Serious liver and kidney;
- Diabetic ketoacidosis, diabetic precoma and coma;
- Hypersensitivity to the Glemaza;
Glemaz not apply in pediatrics.
Precautions should be prescribed Glemaz with extensive burns, severe multiple trauma, major surgery, as well as intestinal obstruction and gastroparesis.
Instructions Glemaza: methods of use
Early treatment is usually administered 1 mg Glemaza once a day. This dose recommended as supports when the optimal therapeutic effect. If necessary, the daily dose can be gradually increased up to a maximum of 8 mg, with a gradual increase in the recommended dose of 1 mg not more than once every two weeks.
The daily dose is assigned immediately before or during a hearty breakfast with plenty of fluid.
Treatment Glemazom according to the instructions long, with constant monitoring of blood glucose. Time and frequency reception Glemaza daily dose determined by a physician and take into account the lifestyle of the patient.
When the therapy Glemaz recommended to take the appointed time, and should not be missed reception offset the increase in dose. In some cases, it permitted the simultaneous application Glemaza with metformin and insulin.
In overdose Glemazom according to the instructions for three days may develop hypoglycemia, which manifests itself as anxiety, sweating, tachycardia, increased blood pressure, arrhythmia, aggression or apathy, palpitations, anxiety, headache, pain in the heart, dizziness, sharp increased appetite, vomiting, drowsiness, impaired concentration, nausea, confusion, depression and tremors. In some cases, symptoms of overdose Glemazom resemble a stroke.
Concomitant use Glemaza with some drugs may cause as a weakening and strengthening of hypoglycemic effect of the drug, so before applying them to consult a doctor.
If necessary, after consultation with physician drug can be replaced by one of the counterparts Glemaza - Amaryl, Gliamal Pliva, Glyumedeks, Meglimid, glimepiride.
According to the instructions when taking Glemaza can develop a variety of disorders that manifest themselves as:
- Hypoglycemic reactions;
- Hives, skin rash and itching;
- Transient visual disturbances, especially at the beginning of treatment;
- Leukopenia, thrombocytopenia (moderate to severe), hemolytic or aplastic anemia, granulocytopenia, erythropenia, agranulocytosis, and pancytopenia;
- Nausea, abdominal pain, feeling of heaviness or discomfort during digestion, vomiting, diarrhea, jaundice, cholestasis and hepatitis.
In rare cases, the drug, as well as analogues Glemaza can cause hyponatremia, headache, photosensitivity, fatigue and late cutaneous porphyria.
Glemaz refers to a number of drugs, prescription, with a shelf life of 24 months.